The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Expected to enhance global innovator flexibility with biologics drug substance facility in Baltimore BANGALORE, India, March ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Godrej Agrovet's board approved the acquisition of the remaining 48.06 percent stake in Creamline Dairy Products, which is ...

In 2024, PolyPeptide made substantial progress in restoring profitability. The gross profit for 2024 was EUR 39.3 million versus EUR 9.1 million in 2023, and EBITDA was EUR 25.4 million versus EUR ...

Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% by 2030. Mr. Shah Coherent Market Insights Pvt. Ltd.

The 450-acre innovation district has revealed further plans and is seeking investment for the development of Health ...

As per the filing, the board of directors has also approved the execution of a share purchase agreement with the promoter ...

“The expansion of our Singapore site will strengthen our global manufacturing capabilities ... employing around 7,000 employees, with Amgen, GSK, Pfizer, Sanofi, MSD, Novartis, and Roche ...

GSK also officially opened its £90 million new aseptic manufacturing facility at its Barnard Castle site in County Durham, part of a manufacturing upgrade first announced in 2016. The 'smart ...